Vivet Therapeutics receives Orphan Drug Designation from European Commission for VTX-806

MLA

“Vivet Therapeutics Receives Orphan Drug Designation from European Commission for VTX-806.” M2 Pharma, 6 Sept. 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.807448483&authtype=sso&custid=ns315887.

APA

Vivet Therapeutics receives Orphan Drug Designation from European Commission for VTX-806. (2024, September 6). M2 Pharma.

Chicago

M2 Pharma. 2024. “Vivet Therapeutics Receives Orphan Drug Designation from European Commission for VTX-806,” September 6. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.807448483&authtype=sso&custid=ns315887.